NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.330
-0.040 (-2.92%)
Nov 20, 2024, 4:00 PM EST - Market closed
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2024. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,350,316
Market Cap
15.71M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vivos Therapeutics | 123 |
| Flora Growth | 108 |
| AIM ImmunoTech | 28 |
| Microbot Medical | 22 |
| Traws Pharma | 18 |
| Minerva Neurosciences | 9 |
| Autonomix Medical | 8 |
| Can-Fite BioPharma | 8 |
NNVC News
- 6 days ago - NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID - Accesswire
- 17 days ago - NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - Accesswire
- 4 weeks ago - NanoViricides President Dr. Diwan to Present at the PODD Conference - Accesswire
- 5 weeks ago - NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology - Accesswire
- 6 weeks ago - NanoViricides to Present at the Global AMR Summit 2024 Tomorrow - Accesswire
- 7 weeks ago - NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID - Accesswire
- 2 months ago - NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs - Accesswire
- 3 months ago - MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX - Accesswire